

Corinne Vandermeulen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3331618/publications.pdf>

Version: 2024-02-01

52
papers

2,088
citations

236612

25
h-index

243296

44
g-index

53
all docs

53
docs citations

53
times ranked

3115
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value. <i>Acta Clinica Belgica</i> , 2023, 78, 78-86. | 0.5 | 9 |
| 2 | Age-dependent seroprevalence of SARS-CoV-2 antibodies in school-aged children from areas with low and high community transmission. <i>European Journal of Pediatrics</i> , 2022, 181, 571-578. | 1.3 | 23 |
| 3 | Perceived team roles of medical students: a five year cross-sectional study. <i>BMC Medical Education</i> , 2022, 22, 198. | 1.0 | 1 |
| 4 | Increased vaccine uptake and less perceived barriers toward vaccination in long-term care facilities that use multi-intervention manual for influenza campaigns. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 673-680. | 1.4 | 12 |
| 5 | Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study. <i>Vaccine</i> , 2021, 39, 2800-2809. | 1.7 | 23 |
| 6 | Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1472-1479. | 0.8 | 1 |
| 7 | Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients. <i>Vaccines</i> , 2021, 9, 18. | 2.1 | 7 |
| 8 | A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. <i>Nature</i> , 2021, 590, 320-325. | 13.7 | 148 |
| 9 | Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2021, 73, e661-e671. | 2.9 | 20 |
| 10 | A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study. <i>Vaccine</i> , 2021, 39, 6628-6636. | 1.7 | 4 |
| 11 | Long-term immunogenicity and safety of a non-typeable <i>Haemophilus influenzae</i> - <i>Moraxella catarrhalis</i> vaccine: 4-year follow-up of a phase 1 multicentre trial. <i>Vaccine: X</i> , 2021, 9, 100124. | 0.9 | 5 |
| 12 | Novel instrument to guide nurse-led consultations with parents of three-year-olds in school health services in Flanders: A feasibility study of SPARK36. <i>Journal of Pediatric Nursing</i> , 2021, , . | 0.7 | 1 |
| 13 | Vaccination coverage of recommended vaccines and determinants of vaccination in at-risk groups. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2136-2143. | 1.4 | 32 |
| 14 | Value Frameworks for Vaccines: Which Dimensions Are Most Relevant?. <i>Vaccines</i> , 2020, 8, 628. | 2.1 | 4 |
| 15 | Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial. <i>Vaccine</i> , 2020, 38, 3227-3234. | 1.7 | 7 |
| 16 | Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. <i>Cephalgia</i> , 2019, 39, 100-110. | 1.8 | 32 |
| 17 | Safety and immunogenicity of non-typeable <i>Haemophilus influenzae</i> - <i>Moraxella catarrhalis</i> vaccine. <i>Vaccine</i> , 2019, 37, 3113-3122. | 1.7 | 30 |
| 18 | ¹⁸ F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. <i>Journal of Nuclear Medicine</i> , 2019, 60, 683-690. | 2.8 | 63 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Coverage of recommended vaccines during pregnancy in Flanders, Belgium. Fairly good but can we do better?. <i>Vaccine</i> , 2018, 36, 2687-2693. | 1.7 | 18 |
| 20 | Attitudes, beliefs, determinants and organisational barriers behind the low seasonal influenza vaccination uptake in healthcare workers – A cross-sectional survey. <i>Vaccine</i> , 2018, 36, 3351-3358. | 1.7 | 66 |
| 21 | Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 815-825. | 2.3 | 71 |
| 22 | Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 596-608. | 1.4 | 19 |
| 23 | Occurrence of atypical HUS associated with influenza B. <i>European Journal of Pediatrics</i> , 2017, 176, 449-454. | 1.3 | 12 |
| 24 | Recruitment barriers for prophylactic vaccine trials: A study in Belgium. <i>Vaccine</i> , 2017, 35, 6598-6603. | 1.7 | 7 |
| 25 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers. <i>Frontiers in Pharmacology</i> , 2017, 8, 740. | 1.6 | 54 |
| 26 | The resurgence of mumps and pertussis. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 955-959. | 1.4 | 28 |
| 27 | Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. <i>PLoS ONE</i> , 2016, 11, e0165384. | 1.1 | 2 |
| 28 | Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium. <i>Vaccine</i> , 2015, 33, 3026-3034. | 1.7 | 7 |
| 29 | Quantification, Variability, and Reproducibility of Basal Skeletal Muscle Glucose Uptake in Healthy Humans Using ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1520-1526. | 2.8 | 14 |
| 30 | Influenza and pertussis vaccination coverage in pregnant women. <i>Vaccine</i> , 2015, 33, 2125-2131. | 1.7 | 100 |
| 31 | Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. <i>Vaccine</i> , 2011, 29, 3842-3849. | 1.7 | 28 |
| 32 | Detection of mumps virus-specific memory B cells by transfer of peripheral blood mononuclear cells into immune-deficient mice. <i>Immunology</i> , 2010, 131, 33-39. | 2.0 | 15 |
| 33 | Mumps outbreaks in highly vaccinated populations: What makes good even better?. <i>Hum Vaccin</i> , 2009, 5, 494-496. | 2.4 | 26 |
| 34 | Evaluation of Cellular Immunity to Mumps in Vaccinated Individuals with or without Circulating Antibodies up to 16 Years after Their Last Vaccination. <i>Journal of Infectious Diseases</i> , 2009, 199, 1457-1460. | 1.9 | 27 |
| 35 | Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2009, 98, 1307-1312. | 0.7 | 29 |
| 36 | Common attitudes about concomitant vaccine injections for infants and adolescents in Flanders, Belgium. <i>Vaccine</i> , 2009, 27, 1964-1969. | 1.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. <i>Vaccine</i> , 2009, 27, 6918-6925. | 1.7 | 20 |
| 38 | CAREGIVERSâ€™ WILLINGNESS TO PAY TO REDUCE THE NUMBER OF VACCINE INJECTIONS IN INFANTS. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 61-63. | 1.1 | 8 |
| 39 | Vaccination coverage and sociodemographic determinants of measlesâ€“mumpsâ€“rubella vaccination in three different age groups. <i>European Journal of Pediatrics</i> , 2008, 167, 1161-1168. | 1.3 | 46 |
| 40 | Vaccination Coverage in 14-Year-Old Adolescents: Documentation, Timeliness, and Sociodemographic Determinants. <i>Pediatrics</i> , 2008, 121, e428-e434. | 1.0 | 58 |
| 41 | An Adjuvanted, Low-Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross-Reactive Immune Responses in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2008, 198, 642-649. | 1.9 | 111 |
| 42 | Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein-Barr Virus Vaccine in Healthy Young Adults. <i>Journal of Infectious Diseases</i> , 2007, 196, 1749-1753. | 1.9 | 347 |
| 43 | Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. <i>Vaccine</i> , 2007, 25, 4940-4948. | 1.7 | 62 |
| 44 | Long-term persistence of antibodies after one or two doses of MMR-vaccine. <i>Vaccine</i> , 2007, 25, 6672-6676. | 1.7 | 43 |
| 45 | Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP+IPV+PRP+T+HBs) combination vaccine. <i>Vaccine</i> , 2007, 25, 7549-7558. | 1.7 | 12 |
| 46 | Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. <i>Vaccine</i> , 2005, 23, 1515-1521. | 1.7 | 31 |
| 47 | Outbreak of mumps in a vaccinated child population: a question of vaccine failure?. <i>Vaccine</i> , 2004, 22, 2713-2716. | 1.7 | 102 |
| 48 | Sexual maturation in relation to polychlorinated aromatic hydrocarbons: Sharpe and Skakkebaek's hypothesis revisited.. <i>Environmental Health Perspectives</i> , 2002, 110, 771-776. | 2.8 | 204 |
| 49 | The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). <i>European Journal of Pediatrics</i> , 2002, 161, 588-593. | 1.3 | 44 |
| 50 | Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. <i>Vaccine</i> , 1999, 17, 875-886. | 1.7 | 36 |
| 51 | The effect of reconstitution of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) vaccine on the immune responses to a diphtheriaâ€“tetanus-whole cell pertussis (DTwP) vaccine: a five-year follow-up. <i>Vaccine</i> , 1999, 17, 2588-2598. | 1.7 | 8 |
| 52 | Implementation of Adolescent Vaccination Programmes Through School. <i>Biologicals</i> , 1997, 25, 155-157. | 0.5 | 0 |